DOCSLIB.ORG

Online Supplement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Online Supplement BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Online Supplement: Manuscript Title: Nocturnal Hypoxaemia in Interstitial Lung Disease: A Systematic Review Authors: Yet H Khor, Yvonne Ng, Duncan Sweeney, Christopher J Ryerson 1 Khor YH, et al. Thorax 2021;0:1–9. doi: 10.1136/thoraxjnl-2020-216749 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Table of content: S1. Database search strategy …………………………………………………………………………………………………. 3 Table S2. Risk of bias assessment tool for non-intervention studies ………………………………………………… 6 S3. Additional reports of included studies ……………………………………………………………………………………….. 8 Table S4. Characteristics of included studies …………………………………………………………………………………… 9 Table S5. Summary of the risk of bias assessment for non-intervention studies ……………………………. 16 Table S6. Summary of the risk of bias assessment for intervention studies ..….…………………………...….. 17 Figure S1. Sensitivity analyses of pooled proportions of clinically significant nocturnal hypoxaemia: a) risk of bias, b) types of study design, and c) study participant numbers ………………………………………… 18 Table S7. Associations of nocturnal hypoxaemia in ILD ……….…………………………………………………………. 21 Table S8. Impacts of supplemental oxygen therapy for nocturnal hypoxaemia in ILD .…………………... 28 Table S9. Impacts of nocturnal hypoxaemia on health-related quality of life and symptoms in ILD .. 29 2 Khor YH, et al. Thorax 2021;0:1–9. doi: 10.1136/thoraxjnl-2020-216749 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax S1. Database search strategy Ovid MEDLINE Row Term Hits 1 Nocturnal*.mp. 37042 2 Night*.mp. 85467 3 Sleep*.mp. 204945 4 or/1-3 282024 5 exp Sleep Apnea Syndromes/ 35201 6 (sleep* adj3 (apnea* or apnoea*)).mp. 45550 7 (hypopnea* or hypopnoea*).mp. 11854 8 OSA.mp. 13900 9 SHS.mp. 2782 10 OSAHS.mp. 1439 11 or/5-10 50837 12 4 or 11 286568 13 exp Lung Diseases, Interstitial/ 55448 14 exp Pulmonary Fibrosis/ 23255 15 (Interstitial* adj3 (lung* or pneumon* or pulmon* or fibros*)).mp. 34717 16 ((pulmonary* or lung* or respirat*) adj3 (fibros* or fibrot*)).mp. 35558 17 (diffuse* adj3 (lung* or pneumon* or pulmon* or parenchym*)).mp. 6646 18 ILD.mp. 4097 19 Alveolitis.mp. 6138 20 (pulmonary* adj3 sarcoid*).mp. 5135 21 (asbestosis or silicosis or siderosis or byssinosis or berylliosis or 16667 anthracosilicosis or sillicotuberculosis).mp. 22 Pneumo#onio*.mp. 8180 23 exp Pneumoconiosis/ 20117 24 alveolitis, extrinsic allergic/ or bird fancier's lung/ or farmer's lung/ or silo 4248 filler's disease/ or trichosporonosis/ 25 ((hypersensitiv* or allerg* or lymphocyt* or granulomat*) adj3 (lung* or 25290 pneumon* or pulmon* or respirat* or fibros* or alveolit*)).mp. 26 or/13-25 132436 27 Granulomat*.mp. 40568 28 exp Histiocytosis/ or histiocytosis*.mp. 22376 29 exp Connective tissue diseases/ 302631 30 (connective adj3 tissue adj3 (disorder* or disease*)).mp. 18880 31 exp Rheumatic diseases/ 224776 32 rheumatic*.mp. 65811 33 exp Scleroderma, Systemic/ 20423 34 (scleroderma or sclerosis or polymyositis or dermatomyositis or myositis or 335461 systemic lupus erythematos* or rheumatoid arthritis).mp. 35 or/27-34 658313 36 35 and (lung* or pneumon* or pulmon* or respirat* or fibros* or 59415 alveolit*).mp. 37 26 or 36 174990 38 12 and 37 1462 3 Khor YH, et al. Thorax 2021;0:1–9. doi: 10.1136/thoraxjnl-2020-216749 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Embase Row Term Hits 1 Nocturnal*.mp. 57961 2 Night*.mp. 145247 3 Sleep*.mp. 338228 4 or/1-3 461800 5 exp Sleep Apnea Syndromes/ 50228 6 (sleep* adj3 (apnea* or apnoea*)).mp. 72002 7 (hypopnea* or hypopnoea*).mp. 23907 8 OSA.mp. 27698 9 SHS.mp. 3720 10 OSAHS.mp. 2032 11 or/5-10 92677 12 4 or 11 468471 13 exp interstitial lung disease/ 85235 14 exp lung fibrosis/ 84112 15 (Interstitial* adj3 (lung* or pneumon* or pulmon* or fibros*)).mp. 64513 16 ((pulmonary* or lung* or respirat*) adj3 (fibros* or fibrot*)).mp. 62177 17 (diffuse* adj3 (lung* or pneumon* or pulmon* or parenchym*)).mp. 11050 18 ILD.mp. 9536 19 alveolitis.mp. 30855 20 (pulmonary* adj3 sarcoid*).mp. 4973 21 (asbestosis or silicosis or siderosis or byssinosis or berylliosis or 22979 anthracosilicosis or sillicotuberculosis).mp. 22 Pneumo#onio*.mp. 11016 23 exp Pneumoconiosis/ 9619 24 allergic pneumonitis/ or bird breeder lung/ or farmer lung/ or loeffler 12132 pneumonia/ or pigeon breeder lung/ 25 ((hypersensitiv* or allerg* or lymphocyt* or granulomat*) adj3 (lung* or 37088 pneumon* or pulmon* or respirat* or fibros* or alveolit*)).mp. 26 or/13-25 204804 27 Granulomat*.mp. 69785 28 exp Histiocytosis/ or histiocytosis*.mp. 23036 29 exp Connective tissue diseases/ 479974 30 (connective adj3 tissue adj3 (disorder* or disease*)).mp. 33601 31 exp Rheumatic diseases/ 275495 32 Rheumatic$.mp. 115585 33 exp Systemic Sclerosis/ 31571 34 (scleroderma or sclerosis or polymyositis or dermatomyositis or myositis or 627294 systemic lupus erythematos* or rheumatoid arthritis).mp. 35 or/27-34 904182 36 35 and (lung* or pneumon* or pulmon* or respirat* or fibros* or 132791 alveolit*).mp. 37 26 or 36 302636 38 12 and 37 5456 4 Khor YH, et al. Thorax 2021;0:1–9. doi: 10.1136/thoraxjnl-2020-216749 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax CENTRAL (Cochrane Register of Studies Online) Row Term Hits #1 Nocturnal* 6468 #2 Night* 19353 #3 Sleep* 37407 #4 MeSH descriptor: [Sleep] explode all trees 5528 #5 {or #1-#4} 51499 #6 MeSH descriptor: [Sleep Apnea Syndromes] explode all trees 2541 #7 MeSH descriptor: [Sleep Apnea, Obstructive] explode all trees 1872 #8 sleep* near/3 (apnea* or apnoea*) 6450 #9 hypopnea* or hypopnoea* 2494 #10 OSA 3545 #11 SHS 351 #12 OSAHS 208 #13 {or #6-#12} 7413 #14 #5 or #13 52047 #15 MeSH descriptor: [Lung Diseases, Interstitial] explode all trees 786 #16 MeSH descriptor: [Pulmonary Fibrosis] explode all trees 504 #17 Interstitial* near/3 (lung* or pneumon* or pulmon* or fibros*) 1926 #18 (pulmonary* or lung* or respirat*) near/3 (fibros* or fibrot*) 2174 #19 diffuse* near/3 (lung* or pneumon* or pulmon* or parenchym*) 157 #20 ILD 472 #21 Alveolitis 699 #22 pulmonary* near/3 sarcoid* 202 #23 asbestosis or silicosis or siderosis or byssinosis or berylliosis or 147 anthracosilicosis or sillicotuberculosis #24 Pneumo?onio* 71 #25 MeSH descriptor: [Pneumoconiosis] explode all trees 97 #26 MeSH descriptor: [Alveolitis, Extrinsic Allergic] explode all trees 26 #27 (bird* or farmer* or pigeon* or avian* or budgerigar*) near/3 (lung* or 108 disease*) #28 (hypersensitiv* or allerg* or lymphocyt* or granulomat*) near/3 (lung* or 2367 pneumon* or pulmon* or respirat* or fibros* or alveolit*) #29 MeSH descriptor: [Histiocytosis, Langerhans-Cell] explode all trees 19 #30 {or #15-#29} 6648 #31 Granulomat* 595 #32 MeSH descriptor: [Connective Tissue Diseases] explode all trees 9395 #33 (connective near/3 tissue near/3 (disorder* or disease*)) 2239 #34 MeSH descriptor: [Rheumatic Diseases] explode all trees 15198 #35 rheumatic* 7433 #36 MeSH descriptor: [Scleroderma, Systemic] explode all trees 532 #37 scleroderma* or sclerosis* or polymyositis or dermatomyositis or myositis or 30000 systemic lupus erythematos* or rheumatoid arthritis #38 {or #31-#37} 45764 #39 lung* or pneumon* or pulmon* or respirat* or fibros* or alveolit* 168642 #40 #38 and #39 3714 #41 #30 or #40 9763 #42 #14 and #41 410 5 Khor YH, et al. Thorax 2021;0:1–9. doi: 10.1136/thoraxjnl-2020-216749 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Table S2. Risk of bias assessment for non-intervention studies* Risk of bias items Risk of bias levels (Select HIGH RISK if information is unclear or Points not provided) scored 1. Was the study target Yes (LOW RISK): The study’s target population was a close 0 population a close representation of the general ILD/IPF population. representation of the No (HIGH RISK): The study’s target population was clearly NOT 1 general ILD/IPF representative of the general ILD/IPF population. population in relation to relevant variables, e.g. age, sex, etc? 2. Was the sampling frame Yes (LOW RISK): The sampling frame was a true or close 0 a true or close representation of the target population. representation of the No (HIGH RISK): The sampling frame was NOT a true or close 1 target population? representation of the target population. 3. Was some form of Yes (LOW RISK): A consecutive sampling was undertaken, OR, 0 random selection used to some form of random selection was used to select the sample select the sample, OR, (e.g. simple random sampling, stratified random sampling, was a consecutive cluster sampling, systematic sampling)? sampling undertaken? No (HIGH RISK): A census was NOT undertaken, AND some form 1 of random selection was NOT used to select the sample. 4. Was the likelihood of Yes (LOW RISK): The participation rate for the study was ≥75%, 0 non-participation bias OR, an analysis was performed that showed no significant minimal? difference in relevant demographic characteristics between participants and non-participants No (HIGH RISK): The participation rate was <75%, and if any 1 analysis comparing responders and non-responders was done, it showed a significant difference in relevant demographic characteristics between participants and non-participants 5.
Load more

Recommended publications
  • Interstitial Lung Diseases in Developing Countries
    Rivera-Ortega P and Molina-Molina M. Interstitial Lung Diseases in Developing Countries. Annals of Global Health. 2019; 85(1): 4, 1–14. DOI: https://doi.org/10.5334/aogh.2414 REVIEW Interstitial Lung Diseases in Developing Countries Pilar Rivera-Ortega*,† and Maria Molina-Molina*,† More than 100 different conditions are grouped under the term interstitial lung disease (ILD). A diag- nosis of an ILD primarily relies on a combination of clinical, radiological, and pathological criteria, which should be evaluated by a multidisciplinary team of specialists. Multiple factors, such as environmental and occupational exposures, infections, drugs, radiation, and genetic predisposition have been implicated in the pathogenesis of these conditions. Asbestosis and other pneumoconiosis, hypersensitivity pneumonitis (HP), chronic beryllium disease, and smoking-related ILD are specifically linked to inhalational exposure of environmental agents. The recent Global Burden of Disease Study reported that ILD rank 40th in relation to global years of life lost in 2013, which represents an increase of 86% compared to 1990. Idiopathic pulmonary fibrosis (IPF) is the prototype of fibrotic ILD. A recent study from the United States reported that the incidence and prevalence of IPF are 14.6 per 100,000 person-years and 58.7 per 100,000 persons, respectively. These data suggests that, in large populated areas such as Brazil, Russia, India, and China (the BRIC region), there may be approximately 2 million people living with IPF. However, studies from South America found much lower rates (0.4–1.2 cases per 100,000 per year). Limited access to high- resolution computed tomography and spirometry or to multidisciplinary teams for accurate diagnosis and optimal treatment are common challenges to the management of ILD in developing countries.
    [Show full text]
  • Preventing Postoperative Pulmonary Complications the Role of the Anesthesiologist David O
    1467 Ⅵ CLINICAL CONCEPTS AND COMMENTARY Richard B. Weiskopf, M.D., Editor Anesthesiology 2000; 92:1467–72 © 2000 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Preventing Postoperative Pulmonary Complications The Role of the Anesthesiologist David O. Warner, M.D.* THE Confederate General “Stonewall” Jackson was one widely. Nonetheless, it is still clear that PPCs occur of the earliest known victims of a respiratory complica- relatively frequently. In studies of noncardiac surgery, tion after surgery, dying of pneumonia 10 days after an the frequency of PPCs and cardiac complications (which otherwise successful ether anesthetic in 1863. Despite historically have attracted more attention from the anes- subsequent advances in anesthesia and surgical care, thesia community) are comparable.1 For example, in a postoperative pulmonary complications (PPCs) still are a series of adult men undergoing elective abdominal sur- significant problem in modern practice. This commen- gery, PPCs occurred significantly more frequently than tary examines why PPCs occur and how the anesthesi- cardiac complications (estimated rates of 9.6% and 5.7%, ologist can help prevent them. respectively) and were associated with significantly longer hospital stays.1 Significance of Perioperative Pulmonary Causes of Perioperative Pulmonary Complications Complications Determination of the frequency and clinical impact of A basic understanding of mechanism guides rational PPCs in modern practice is hampered by the lack of a practice. Many PPCs, such as atelectasis and pneumonia, uniform definition of a PPC among studies. Nearly all seem to be related to disruption of the normal activity of investigators include in this definition pneumonia (defi- the respiratory muscles, disruption that begins with the nite or suspected), respiratory failure (usually defined as induction of anesthesia and that may continue into the the need for mechanical ventilatory support), and bron- postoperative period.
    [Show full text]
  • Pneumoconiosis and Byssinosis
    British Journal of Industrial Medicine, 1974, 31, 322-328 Br J Ind Med: first published as 10.1136/oem.31.4.322 on 1 October 1974. Downloaded from Notes and miscellanea Pneumoconiosis and byssinosis D. C. F. MUIR Institute of Occupational Medicine, Roxburgh Place, Edinburgh, EH8 9SU On 1 August 1968 the Minister of Social Security loggerheads over the question of pneumoconiosis in referred the following question to the Industrial general and of related disability in particular. Injuries Advisory Council for consideration and The less controversial aspects of the report should advice: perhaps be mentioned first in order to clear the way Whether in the light of experience and current for a review of its more fundamental features. It is knowledge any adjustment should be made in the well written and has concise and clear explanations terms of the definition of pneumoconiosis in of the problems considered. The historical back- section 58 (3) of the National Insurance (In- ground is reviewed in detail, and there is an excellent copyright. dustrial Injuries) Act 1965; and whether any and, description of the work of the Pneumoconiosis if so, what special provision should be made for Medical Panels. There is a great deal of information disablement due to other respiratory conditions in the report which is not available in textbooks of found in the presence of such pneumoconiosis to occupational medicine, and it should be essential be taken into account in assessing the extent of reading for all who have an interest in this field. The disablement due to the disease. summary and conclusions are short and explicit.
    [Show full text]
  • Compensation for Pneumoconiosis and Byssinosis Insurance Or Gamble?
    404 BRITISH MEDICAI JOURNAL 9 MARCH 1974 Lightdale, C. J., Kurtz, R. C., Boyle, C. C., Sherlock, P., and Winawer, S. J., Journal of the American Medical Association, 1973, 226, 139. according to a court ruling, need not necessarily entail dis- 2 Dunphy, J. E., Mikkelsen, W. P., Moody, F. G., and Silen, W., Archives ability, and the report recommends that a diagnosis ofpneumo- of Surgery, 1973, 107, 367. Schiller, K. F. R., Truelove, S. C., and Gwyn Williams, D., British coniosis should not in itself entitle to benefit. This means that Br Med J: first published as 10.1136/bmj.1.5905.404 on 9 March 1974. Downloaded from Medical journal, 1973, 2, 7. it will be necessary in cases where a radiological diagnosis of 4Boulos, P. B., Harris, J., Wyllie, J. H., and Clark, C. G., BritishJournal of Surgery, 1971, 58, 817. pneumoconiosis has been made to show functional impairment 6 Wilson, W. S., Gadacz, T., Olcoff, C., and Blaisdell, F. W., American before the patient becomes of Surgery, 1973, 126, 133. eligible for benefit. 6 Drapanas,6Journal T., Woolverton, W. C., Reeder, J. W., Reed, R. I., and Wei- Though the number of newly diagnosed cases of coal chert, R. F., Annals of Surgery, 1971, 173, 628. Taylor, P. C., Loop, F. D., and Hermann, R. E., Annals of Surgery, 1973, workers' pneumoconiosis has fallen considerably, the increase 178, 1. in new cases of asbestosis and of diffuse mesothelioma has 8 Skillman, J. J., and Silen, W., Lancet, 1972, 2, 1303. 9 Palmer, E. D., J'ournal of the American Medical Association, 1969, 207, meant a continuing high work-load for the medical panels.
    [Show full text]
  • 1 Smith Seminars Online Continuing Education AARC-Approved For
    Smith Seminars Online Continuing Education AARC-Approved for 2 CRCE Air Pollution Effects on the Lungs Objectives Identify how pollution affects health and welfare Be familiar with tools to help the patient decrease the effects of air pollution Become aware of the impact of environmental pulmonary diseases due to exposure to air pollution. Learn the current diagnosis and treatment for inhalation pulmonary diseases due to exposure to air pollution. Exposure to air pollution is associated with numerous effects on human health, including pulmonary, cardiac, vascular, and neurological impairments. The health effects vary greatly from person to person. High-risk groups such as the elderly, infants, pregnant women, and sufferers from chronic heart and lung diseases are more susceptible to air pollution. Children are at greater risk because they are generally more active outdoors and their lungs are still developing. Exposure to air pollution can cause both acute (short-term) and chronic (long-term) health effects. Acute effects are usually immediate and often reversible when exposure to the pollutant ends. Some acute health effects include eye irritation, headaches, and nausea. Chronic effects are usually not immediate and tend not to be reversible when exposure to the pollutant ends. Some chronic health effects include decreased lung capacity and lung cancer resulting from long-term exposure to toxic air pollutants. The scientific techniques for assessing health impacts of air pollution include air pollutant monitoring, exposure assessment, dosimetry, toxicology, and epidemiology. Although in humans pollutants can affect the skin, eyes and other body systems, they affect primarily the respiratory system. Air is breathed in through the nose, which acts as the primary filtering system of the body.
    [Show full text]
  • Occupational Lung Disease6
    Thorax 19,96;51:632-637 .32632 Thorax 1 9.6;51:632-637 Occupational lung disease 6 Series editor: P S Burge Thorax: first published as 10.1136/thx.51.6.632 on 1 June 1996. Downloaded from Bysslnosis: a review R McL Niven, C A C Pickering Over the past two decades the cotton industry article will relate to the disease as described in in the United Kingdom has suffered from a these early epidemiological studies. major recession. Cheaply produced and sub- sidised imported cotton has decimated a major industry which was responsible for much ofthe Symptoms industrial wealth in the north west of England. The classical form ofbyssinosis is characterised With the diminishing industry, we are also by a feeling of chest tightness and difficulty in losing one of the most studied but least under- breathing which the worker experiences as stood occupational diseases, byssinosis. Our being most severe on the first day ofthe working own study of the working population of the week after a period of absence from work. The remaining Lancashire textile mills is now in its symptoms continue after the individual has seventh year, with up to 1500 workers having finished work and may even progress during been seen each year (although the recession the evening. However, they are perceived as has reduced this to 1000 in the last two years). being less troublesome on subsequent days. Of the original 10 mills included in the study, The reason for this lessening of symptoms only two remain in production. remains unknown. The early reports of the health of cotton The affected worker will not experience the workers describe a "work-related cough as- symptoms until he or she has worked for many sociated with a sensation ofuneasiness beneath years in the industry; indeed, it may be seen the sternum"' and later the unusual periodicity for the first time 25 years after starting to ofthe disease "all the workers have told us that work in the industry and is rare in individuals http://thorax.bmj.com/ the dust bothered them much less on the last continuously exposed for less than 10 years.
    [Show full text]
  • Airborne Dust WHO/SDE/OEH/99.14 Chapter 1 - Dust: Definitions and Concepts
    Hazard Prevention and Control in the Work Environment: Airborne Dust WHO/SDE/OEH/99.14 Chapter 1 - Dust: Definitions and Concepts Airborne contaminants occur in the gaseous form (gases and vapours) or as aerosols. In scientific terminology, an aerosol is defined as a system of particles suspended in a gaseous medium, usually air in the context of occupational hygiene, is usually air. Aerosols may exist in the form of airborne dusts, sprays, mists, smokes and fumes. In the occupational setting, all these forms may be important because they relate to a wide range of occupational diseases. Airborne dusts are of particular concern because they are well known to be associated with classical widespread occupational lung diseases such as the pneumoconioses, as well as with systemic intoxications such as lead poisoning, especially at higher levels of exposure. But, in the modern era, there is also increasing interest in other dust-related diseases, such as cancer, asthma, allergic alveolitis, and irritation, as well as a whole range of non-respiratory illnesses, which may occur at much lower exposure levels. This document aims to help reduce the risk of these diseases by aiding better control of dust in the work environment. The first and fundamental step in the control of hazards is their recognition. The systematic approach to recognition is described in Chapter 4. But recognition requires a clear understanding of the nature, origin, mechanisms of generation and release and sources of the particles, as well as knowledge on the conditions of exposure and possible associated ill effects. This is essential to establish priorities for action and to select appropriate control strategies.
    [Show full text]
  • The Living with Pulmonary Fibrosis Questionnaire in Progressive Fibrosing Interstitial Lung Disease
    ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASE The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease Jeffrey Swigris 1, Katelyn Cutts2, Natalia Male3, Michael Baldwin3, Klaus B. Rohr3 and Donald M. Bushnell 2 Affiliations: 1National Jewish Health, Denver, CO, USA. 2Evidera, Bethesda, MD, USA. 3Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. Correspondence: Jeffrey Swigris, National Jewish Health, 1400 Jackson Street, Denver, Colorado, USA. E-mail: [email protected] ABSTRACT The Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire was developed with substantial input from patients with idiopathic pulmonary fibrosis (IPF) to assess symptoms and health- related quality of life (HRQoL). Because IPF is the prototypical chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, we expanded applicability of the L-IPF by deleting the word “idiopathic”, creating the L-PF (Living with Pulmonary Fibrosis) questionnaire, and then assessed its relevance among patients with progressive fibrosing ILDs in one-to-one interviews. Patients in the USA and Germany with any progressive fibrosing ILD other than IPF were asked about their disease and symptoms, completed the 44-item L-PF questionnaire (comprising two modules that assess symptoms and impacts of disease) and then answered a series of debriefing questions. Interviews were recorded, transcribed and coded for qualitative content analysis. 20 patients were interviewed, but time constraints meant not all were asked about all items. The most frequent diagnoses were rheumatoid arthritis-associated ILD (25%) and mixed connective tissue disease- associated ILD (20%). Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath (19 out of 20 patients), cough (19 out of 20) and fatigue (18 out of 20).
    [Show full text]
  • Respiratory Disease Caused by Synthetic Fibres: a New Occupational Disease1
    Thorax: first published as 10.1136/thx.30.2.204 on 1 April 1975. Downloaded from Thorax (1975), 30, 204. Respiratory disease caused by synthetic fibres: a new occupational disease1 J. CORTEZ PIMENTEL, RAMIRO AVILA, and A. GALVAO LOURENQO IANT (Department of Pathology of Sanatorio D. Carlos 1), Institute of Pathology and Department of Chest Diseases, Lisbon University Faculty of Medicine Pimentel, J. C, Avila, R., and Lourenfo, A. G. (1975). Thorax, 30, 204-219. Respiratory disease caused by synthetic fibres: a new occupational disease. Seven patients exposed to the inhalation of synthetic fibres presented with various bronchopulmonary diseases, such as asthma, extrinsic allergic alveolitis, chronic bronchitis with bronchiectasis, spontaneous pneumothorax, and chronic pneumonia. The histological features are described and an attempt has been made to set up immunological techniques for the diagnosis. A series of histochemical techniques, based on textile chemistry, are proposed for the identifi- cation of the inclusions found in bronchopulmonary lesions. The results of the experi- mental production of the disease in guinea-pigs by the inhalation of synthetic fibre dusts are presented. The prognosis of these cases is good in the acute or recently established cases but is poor when widespread and irreversible fibrosis has set in. The authors consider that pulmonary disease due to inhaled particles is probably set off by an individual factor, possibly immunological. http://thorax.bmj.com/ Synthetic fibres, on the market since the last Sano (1967) called attention to the fact that war, have revolutionized industry, particularly the inhalation of nylon dust, in a series of cases of textile industry.
    [Show full text]
  • Rx for SUCCESS Interstitial Lung Disease
    CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Interstitial Lung Disease Interstitial lung disease (pulmonary fi brosis) is a scarring of the lung caused by increase in the fi brous connective tissue, resulting in impaired lung function. A localized lesion, whether due to a lung abscess, localized pneumonia, fi brosis or bronchiectasis, has less impact than diffuse scarring involving both lungs. Diffuse fi brosis occurs as a result of chronic bronchitis, widespread tuberculosis, pneumoconiosis, or other pulmonary disease. Pneumoconiosis is discussed below. Idiopathic pulmonary fi brosis (IPF) is a progressive disease of no known cause and has a poor prognosis if progressive. Diffuse fi brosis is characterized by a reduction in lung vital capacity because the lung is replaced by scar tissue. The main symptom is shortness of breath. As the condition progresses, the shortness of breath occurs with less activity and in severe cases can result in shortness of breath at rest. There may also be a nonproductive cough or a low-grade fever. Continuous oxygen therapy is required for patients who have low oxygen due to the pulmonary fi brosis. Disease progression is monitored by pulmonary function tests (PFT) and arterial blood gases (ABG). Pneumoconioses are a group of lung diseases resulting from inhalation of mineral or vegetable dusts from occupational exposure. In susceptible people, such inhalation causes pulmonary fi brosis. The amount of scarring depends on the individual, the type of inhaled material, and the amount of exposure. Inhalation of iron and carbon dusts are characterized by very little fi brosis, while silica and asbestos can cause extensive tissue reaction.
    [Show full text]
  • Diffuse Lung Disease Caused by Cotton Fibre Inhalation but Distinct from Byssinosis H Kobayashi, S Kanoh, K Motoyoshi, S Aida
    1095 CASE REPORT Thorax: first published as 10.1136/thx.2003.014027 on 24 November 2004. Downloaded from Diffuse lung disease caused by cotton fibre inhalation but distinct from byssinosis H Kobayashi, S Kanoh, K Motoyoshi, S Aida ............................................................................................................................... Thorax 2004;59:1095–1097. doi: 10.1136/thx.2003.014027 ratio of 4.65) and 85% macrophages. A high resolution CT A 66 year old man had inhaled cotton fibre for 50 years at (HRCT) scan of the lungs showed subpleural ground glass his workplace. He did not have any respiratory symptoms. opacities and an interface sign at the surface of the visceral Chest CT scans revealed diffuse centrilobular and peri- pleura, while centrilobular and peribronchovascular inter- bronchovascular interstitial thickening. Lung biopsy speci- stitial thickening were identified as the inverted Y and V sign mens confirmed the presence of string-like foreign bodies as (fig 1). well as granulomas and fibrosis in the peribronchial region. Transbronchial lung biopsy was performed but failed to Infrared spectrophotometry confirmed that the foreign bodies provide a pathological diagnosis. A video-assisted thoraco- were composed of natural cellulose. This is the first study to scopic biopsy was therefore undertaken with the patient’s show directly by examination of biopsy samples that cotton informed consent and three biopsy specimens were obtained. fibre inhalation can cause diffuse lung disease. The clinical All three specimens had similar histological features of tiny features of the disease were entirely different from those of granulomas and fibrous thickening of the peribronchiolar byssinosis. interstitium (fig 2). Scattered eosinophilic string-like foreign bodies were detected within the areas of peribronchiolar fibrosis (fig 3A and B).
    [Show full text]
  • Atlas of Respiratory Disease Mortality, United States, 1982-1993
    Atlas of Respiratory Disease Mortality, United States: 1982-1993 Jay H. Kim, Ph.D. Division of Respiratory Disease Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Institute for Occupational Safety and Health August, 1998 Disclaimer Mention of company name or product does not constitute endorsement by the National Institute for Occupational Safety and Health. Copies of this and other NIOSH documents are available from: Publications Dissemination, EID National Institute for Occupational Safety and Health 4676 Columbia Parkway Cincinnati, OH 45226-1998 FAX (513) 533-8573 DHHS (NIOSH) Number 98-157 For further information about occupational safety and health, call 1-800-35-NIOSH or visit http://www.cdc.gov/niosh ii PREFACE This Atlas of Respiratory Disease Mortality, United States: 1982-1993 presents maps showing geographic distributions (by health service area) of mortality associated with selected respiratory conditions that together represent nearly all respiratory diseases. For categories of traditional occupational lung diseases mapped in this atlas (i.e., the pneumoconioses, including coal workers’ pneumoconiosis, asbestosis, silicosis, byssinosis, and other and unspecified pneumoconioses), nearly all cases are attributable to hazardous occupational exposure. NIOSH has previously published maps showing geographic distributions (by county) of pneumoconiosis mortality in the United States [NIOSH 1996].* For other respiratory disease categories mapped in this atlas, cases frequently occur in the absence of hazardous occupational exposure, and smaller proportions of cases--much smaller for some disease categories--are therefore considered attributable to occupational exposure. Nevertheless, for each of the disease categories mapped in this atlas, occupational causes have been documented.
    [Show full text]